
Release date: 2024-08-14 13:46:22 Article From: Lucius Laos Recommended: 287
Pemigatinib is used in adults to treat bile duct cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery.
The clinical trial FIGHT-202 is a pivotal clinical trial of Pemigatinib evaluating its efficacy in the treatment of patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. Results from the trial showed an overall response rate (ORR) of 36% and a disease control rate (DCR) of 82% with Pemigatinib monotherapy. This suggests that Pemigatinib is effective in controlling tumor growth and spread in most patients.
The median overall survival (mOS) of Pemigatinib was 21.1 months, significantly prolonging the survival of patients compared to the 6-7 months of historical mean survival in patients who received the second and third lines of treatment. This clinical trial data shows that Pemigatinib can effectively treat cholangiocarcinoma patients and brings new hope for cholangiocarcinoma patients.
Pemigatinib has significant efficacy in the treatment of diseases with FGFR2 fusion or rearrangement, such as cholangiocarcinoma, but it may also be accompanied by a series of adverse reactions.
eye pain or redness, dry or puffy eyes, watery eyes, your eyes may be more sensitive to light.
blurred vision, seeing black spots or "floaters," or seeing flashes of light.
muscle cramps, numbness, and tingly feeling around your mouth.
Before patients are treated with Pemigatinib, they should confirm the conditions of use with their doctor, noting the following.
Before starting Pemigatinib, it is necessary to confirm whether the patient does have FGFR2 fusion or rearrangement, which is an indication for this drug.
Patients should undergo a thorough physical examination to assess basic conditions such as liver and kidney function to ensure that they can tolerate drug therapy.
Patients should follow their doctor's recommendations and medication guidelines to understand how to use the medication, dosage, and precautions.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643